Share on StockTwits

Smith & Nephew plc (LON:SN)‘s stock had its “neutral” rating reiterated by analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Wednesday. They currently have a GBX 908 ($15.22) price objective on the stock. JPMorgan Chase & Co.’s target price points to a potential downside of 11.84% from the company’s current price.

Smith & Nephew plc (LON:SN) traded up 3.30% on Wednesday, hitting GBX 1064.00. The stock had a trading volume of 5,079,043 shares. Smith & Nephew plc has a one year low of GBX 720.00 and a one year high of GBX 1120.00. The stock’s 50-day moving average is GBX 931.7 and its 200-day moving average is GBX 898.0. The company’s market cap is £9.502 billion.

A number of other firms have also recently commented on SN. Analysts at Berenberg Bank reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Wednesday. They now have a GBX 920 ($15.42) price target on the stock. Separately, analysts at Barclays reiterated an “equal weight” rating on shares of Smith & Nephew plc in a research note on Monday. They now have a GBX 780 ($13.08) price target on the stock. Finally, analysts at Numis Securities Ltd reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Monday. They now have a GBX 1,000 ($16.76) price target on the stock. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of GBX 932.76 ($15.64).

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.